Evidence map›Paper›PMID 41446213›Full record

ArticlebioRxiv : the preprint server for biology2025

Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy.

Adam Blaisdell, Stefanie Bachl, Luis R Sandoval, Carter Ching, Christopher J Bowman, Nupura Kale, Manu Prabandham, Morgan Diolaiti, Claire Havig, Rommel Advincula and 17 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Adam BlaisdellDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Stefanie BachlDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Luis R SandovalGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA.
Carter ChingDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Christopher J BowmanDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Nupura KaleDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Manu PrabandhamDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Morgan DiolaitiUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Claire HavigParker Institute for Cancer Immunotherapy, San Francisco, CA.
Rommel AdvinculaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Nika LenciDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Zhongmei LiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA.
Emily YamashitaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Charlotte H WangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA.
Shimin ZhangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA.
Qi LiuDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Philip AchacosoDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Dorothea StiborDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Inger ØynebråtenDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Jin SeoGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA.
Alan AshworthDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Alexander MarsonDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Chun Jimmie YeDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6560-3783
Barbara A MalynnDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Justin EyquemDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Julia CarnevaleDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Averil MaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.

Funding

Single-cell Mapping Center for Human Regulatory Elements and Gene ActivityUM1HG012076 · NHGRI · STANFORD UNIVERSITY · PI Michael Ryan Corces, Ansuman Satpathy · 2021 to 2026
$13.8M
Project 2: Assessing Brain Dysfunction in Clinically Quiescent SLEP01AI172523 · NIAID · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI Betty Diamond · 2024 to 2026
$11.4M
Sjögren’s Team for Accelerating Medicines Partnership (STAMP)UC2DE032254 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALAN N BAER, A Darise Farris · 2022 to 2026
$8.8M
RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
TRAINING PROGRAM IN DISGESTIVE DISEASES AND NUTRITIONT32DK007007 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AVERIL I MA · 1986 to 2026
$6.4M
Sjögren's International Collaborative Clinical Alliance Next Generation Studies (SICCA-NextGen)U01DE028891 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHIBOSKI, CAROLINE HELENE · 2020 to 2024
$4.0M
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapyR01CA276368 · NCI · J. DAVID GLADSTONE INSTITUTES · PI Alexander Marson, Kole T Roybal · 2023 to 2026
$3.0M
A20 and Tumor Immune ResponsesR01CA288237 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AVERIL I MA · 2024 to 2026
$2.8M
Mapping the cell-type-specific molecular and genetic basis of lupus using single cell multiomicsR01AI171184 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Chun Jimmie Ye · 2024 to 2026
$2.4M
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.K08CA252605 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARNEVALE, JULIA C · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA252605NCI NIH HHS R01 CA276368NCI NIH HHS R01 CA288237NHGRI NIH HHS UM1 HG012076NIAID NIH HHS P01 AI172523NIAID NIH HHS R01 AI171184NIAMS NIH HHS P30 AR070155NIDCR NIH HHS U01 DE028891NIDCR NIH HHS UC2 DE032254NIDDK NIH HHS T32 DK007007
6 · The paper itself

Abstract

T cell exhaustion limits the efficacy of cancer immunotherapies. Here, we performed genome-wide loss-of-function screening in repetitively stimulated human T cells and identified the mulitfunctional ubiquitin-modifying protein A20/TNFAIP3 as a major negative regulator of exhausted T cell persistence. Protein large language modeling, deep base-editing mutagenesis, and studies in immunocompetent mice with domain-specific inactivating mutations revealed A20's non-enzymatic M1 ubiquitin-binding zinc finger 7 (A20

Identifiers

PMID41446213
PMCPMC12723523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.